ResMed Inc. 8-K Summary: Annual Meeting Results
Business Context and Reporting Period
ResMed Inc. (NYSE: RMD) filed this Current Report on Form 8-K on November 20, 2024, to disclose the results of its annual meeting of stockholders held on the same date. The company is incorporated in Delaware and headquartered in San Diego, California.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Stockholders voted on three primary items. The results are summarized below:
- Item 1: Election of Directors - Eleven nominees were elected to the Board of Directors. While all nominees received a majority of votes cast, two directors faced significant opposition:
- Richard Sulpizio: Received 22,003,356 votes against (approx. 20% of votes cast).
- Ronald Taylor: Received 14,705,330 votes against (approx. 13% of votes cast).
- Karen Drexler: Received 9,042,745 votes against (approx. 8% of votes cast).
- Item 2: Ratification of Auditors - Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2025.
- For: 105,082,628
- Against: 10,096,722
- Item 3: Say-on-Pay - Stockholders approved, on an advisory basis, the compensation of named executive officers.
- For: 92,885,004
- Against: 17,284,647
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the outcome of the shareholder vote.
Investor Verification Checklist
- Verify the reasons for the significant "Against" votes cast for directors Richard Sulpizio, Ronald Taylor, and Karen Drexler.
- Review the company's proxy statement for details on the executive compensation package that received approximately 15.7% "Against" votes.
- Confirm the tenure and specific roles of the newly elected board members.